Collectively, individuals with PD-1 signal blockade-induced psoriasis-like dermatitis can potentially benefit from IL-6-targeted therapeutic intervention, which is expected to inhibit both Th17 cell differentiation and cytotoxic CD8 T cell activation in the pathological mechanisms of irAE. This evidence concerns the gene PDCD1 and skin disorder.